Tag Archives: Against

Clovis investors lose faith as Rubraca struggles against Big Pharma’s marketing giants

It’s no secret that Clovis Oncology is up against some serious marketing muscle in the PARP inhibitor arena. And investors are doubting the company’s ability to hang in there. Shareholders headed for the exits Thursday after Clovis reported that Rubraca sales tallied just $ 33 million in the second quarter, coming in $ 2 million… Read More »

Education No Match Against Alzheimer's

By Serena Gordon HealthDay Reporter WEDNESDAY, Feb. 6, 2019 (HealthDay News) — There are plenty of good reasons to seek a higher education, but avoiding Alzheimer’s disease probably isn’t one of them, new research suggests. The study found that a person’s level of education wasn’t related to the onset of memory and thinking (“cognitive”) troubles,… Read More »